Why should we be concerned about a “g”?

Frangos, Savvas; Buscombe, J. R.

doi:10.1007/s00259-018-4204-z

Cited by 35 publications

(21 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They presented a relative density of ca. 65% of their theoretical value (ρ CaO = 3.34 g/cm 3 [ 1 ]).…”

Section: Resultsmentioning

confidence: 99%

“…The concept of theragnostics [ 1 ] in nuclear medicine is based on the use of radionuclides of preferably the same element (radioisotopes) to enable the application of chemically identical radiopharmaceuticals for both diagnosis and therapy [ 2 ]. The combination of suitable radionuclides is known as “matched pairs” and this can be performed with different radioisotopes of scandium, namely 44 Sc for diagnosis and 47 Sc for therapy [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Developments toward the Implementation of 44Sc Production at a Medical Cyclotron

et al. 2020

View full text Add to dashboard Cite

44Sc has favorable properties for cancer diagnosis using Positron Emission Tomography (PET) making it a promising candidate for application in nuclear medicine. The implementation of its production with existing compact medical cyclotrons would mean the next essential milestone in the development of this radionuclide. While the production and application of 44Sc has been comprehensively investigated, the development of specific targetry and irradiation methods is of paramount importance. As a result, the target was optimized for the 44Ca(p,n)44Sc nuclear reaction using CaO instead of CaCO3, ensuring decrease in target radioactive degassing during irradiation and increased radionuclidic yield. Irradiations were performed at the research cyclotron at the Paul Scherrer Institute (~11 MeV, 50 µA, 90 min) and the medical cyclotron at the University of Bern (~13 MeV, 10 µA, 240 min), with yields varying from 200 MBq to 16 GBq. The development of targetry, chemical separation as well as the practical issues and implications of irradiations, are analyzed and discussed. As a proof-of-concept study, the 44Sc produced at the medical cyclotron was used for a preclinical study using a previously developed albumin-binding prostate-specific membrane antigen (PSMA) ligand. This work demonstrates the feasibility to produce 44Sc with high yields and radionuclidic purity using a medical cyclotron, equipped with a commercial solid target station.

show abstract

“…They presented a relative density of ca. 65% of their theoretical value (ρ CaO = 3.34 g/cm 3 [ 1 ]).…”

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Developments toward the Implementation of 44Sc Production at a Medical Cyclotron

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In 8 patients (nos. 1,3,6,7,8,14,20,32), bone-targeted therapy was continued after 177 Lu-PSMA-617 therapy had commenced. and could be discharged 48 h post-injection.…”

Section: Patient Selectionmentioning

confidence: 99%

“…In line with the theragnostic concept [6], 68 Ga-labelled PSMA ligands are increasingly used to detect lesions in patients with mCRPC, prior to PSMA-directed radioligand therapy (PRLT), and as diagnostic response tool in the follow-up of PRLT-treated patients [1].…”

Section: Introductionmentioning

confidence: 99%

The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

Maffey-Steffan

Scarpa

Svirydenka³

et al. 2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Introduction A new therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) of heavily pre-treated patients lies in 177 Lu-PSMA-617 radioligand therapy. Methods On the basis of PSMA-targeted 68 Ga-PSMA-11 PET/CT, 32 consecutive mCRPC patients were selected for 177 Lu-PSMA-617 therapy (6 GBq/cycle, 2 to 6 cycles, 6-10 weeks apart) and followed until death. Post-therapy whole-body (WB) dosimetry and 68 Ga-PSMA-11 PET/CT data were compared and related to progression free and overall survival. Results 177 Lu-PSMA-617 dosimetry after the first cycle indicated high tumor doses for skeletal (4.01 ± 2.64; range 1.10-13.00 Gy/GBq), lymph node (3.12 ± 2.07; range 0.70-8.70 Gy/GBq), and liver (2.97 ± 1.38; range 0.76-5.00 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 24 GBq. Any PSA decrease after the first cycle was found in 23/32 (72%), after the second cycle in 22/32 (69%), after the third cycle in 16/28 (57%), and after the fourth cycle in 8/18 (44%) patients. Post-therapy 24 h WB scintigraphy showed decreased tumor-to-background ratios in 24/ 32 (75%) after the first therapy cycle, after the second cycle in 17/29 (59%), and after the third cycle in 13/21 (62%) patients. The median PFS was 7 months and the median OS 12 months. In the group of PSA responders (n = 22) the median OS was 17 months versus 11 months in the group of non-responders (n = 10), p < 0.05. Decreasing SUV max values were found for parotid (15.93 ± 6.23 versus 12.33 ± 4.07) and submandibular glands (17.65 ± 7.34 versus 13.12 ± 4.62) following treatment, along with transient (n = 6) or permanent (n = 2) xerostomia in 8/32 (25%) patients. In 3/32 patients, nephrotoxicity changed from Grade 2 to 3, whereas neither Grade 4 nephrotoxicity nor hematotoxicity was found. In most patients a good agreement was observed for the visual interpretation of the tracer accumulation between 24 h WB and PET/CT scans. However, no significance could be calculated for baseline-absorbed tumor doses and SUV max values of tumor lesions. 5/32 (16%) patients showed a mixed response pattern, which resulted in disease progression over time. Conclusion Serial PSA measurements and post-therapy 24 h WB scintigraphy seems to allow a sufficiently accurate follow-up of 177 Lu-PSMA-617-treated mCRPC patients whereas 68 Ga-PSMA-11 PET/CT should be performed for patient selection and final response assessment.

show abstract

“…To date,t hera(g)nosticsr epresent an auspicious concept toward personalized cancer treatment. [1] The concept implies the combination of diagnosis and at herapeutic approach of the cancerous disease in order to localize the target, monitor the therapeutic outcome as well as to improve drug dosimetry. [2] One such at heragnostic platform is the combination of fluorescenceb ioimaging and photodynamic therapy (PDT).…”

Section: Introductionmentioning

confidence: 99%

Near‐Infrared BODIPY‐Acridine Dyads Acting as Heavy‐Atom‐Free Dual‐Functioning Photosensitizers

Deckers

Cardeynaels

Penxten

et al. 2020

Chemistry A European J

View full text Add to dashboard Cite

Boron dipyrromethene (BODIPY)d yes represent a particular class within the broad array of potential photosensitizers.T heir highly fluorescent nature opens the door for theragnostic applications,c ombining imaginga nd therapy using as ingle, easily synthesized chromophore. However, near-infrareda bsorption is strongly desired for photodynamic therapy to enhance tissue penetration. Furthermore, singlet oxygen should preferentially be generated without the incorporation of heavy atoms,a st hese often require additional synthetice fforts and/ora fford dark cytotoxicity.S olu-tions for both problemsa re known,b ut have never been successfully combinedi no ne simple BODIPYm aterial. Here, we present as eries of compact BODIPY-acridine dyads, active in the phototherapeutic window and showingb alanced brightness andp hototoxic power.A lthough the donor-acceptor design was envisioned to introduce a charget ransfer state to assist in intersystem crossing, quantum-chemicalc alculations refute this. Furtherp hotophysical investigations suggest the presence of exciplex states and their involvement in singlet oxygen formation.

show abstract

Why should we be concerned about a “g”?

Cited by 35 publications

References 5 publications

Developments toward the Implementation of 44Sc Production at a Medical Cyclotron

Developments toward the Implementation of 44Sc Production at a Medical Cyclotron

The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

Near‐Infrared BODIPY‐Acridine Dyads Acting as Heavy‐Atom‐Free Dual‐Functioning Photosensitizers

Contact Info

Product

Resources

About